Aim:The aim of this study is to quantify the red blood cell (RBC) transfusion threshold in critically ill patients and to examine the relationship between RBC transfusion and clinical outcomes. Materials and Methods:Five hundred and twenty patients who were admitted to the internal medicine intensive care unit (ICU) between February 2018 and May 2019 were included in this study. The collected data included patients' demographic characteristics, admission diagnostic categories, co-morbidities, the ICU admission Simplified Acute Physiology Scores (SAPS) II, numbers of RBC transfusion, ICU admission and pretransfusion hemoglobin levels, and requirements of invasive mechanical ventilation and vasoactive drugs during the ICU stay. The primary endpoint of the study was to determine the RBC transfusion threshold in critically ill patients. Secondary outcomes were the ICU length of stay and mortality.Results: A total of 89 (17.1%) patients received RBC transfusion during the ICU stay. The transfusion threshold hemoglobin was 6.9 g/dL in transfused patients. Transfused patients had higher SAPS II scores at ICU admission than non-transfused patients (p<0.001). The number of patients requiring invasive mechanical ventilation and vasopressor support was higher in transfused patients (p<0.001). ICU mortality rates were higher in patients who had received RBC transfusion during the ICU stay than in those who did not (ICU mortality rates were 51.7% and 23.9%, respectively). Conclusion:This study showed that one-fifth of ICU patients received RBC transfusion during the ICU stay. Transfused patients had higher disease scores and lower hemoglobin levels on the day of ICU admission. Transfused patients stayed longer in the ICU and had higher mortality rates than non-transfused patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.